Millions of people around the world live with osteoarthritis, a painful condition that gradually damages the joints. It is the most common form of arthritis and affects people of all ages, although it becomes much more common as people get older.
Osteoarthritis most often develops in weight-bearing joints such as the knees and hips, where years of use place constant stress on the cartilage that cushions the ends of bones.
As the protective cartilage wears away, bones begin to rub against each other. This can lead to pain, stiffness, swelling, reduced mobility, and difficulty performing everyday activities. For many people, symptoms slowly worsen over time. In severe cases, the damage becomes so extensive that joint replacement surgery is needed to restore movement and reduce pain.
Because osteoarthritis affects hundreds of millions of people worldwide, researchers are constantly searching for treatments that can slow the disease and help patients avoid surgery. A new study suggests that an inexpensive and widely available medication called colchicine may offer a promising solution.
Colchicine is not a new drug. Doctors have prescribed it for decades to treat conditions such as gout and certain inflammatory diseases. The medication works by reducing inflammation, which is the body’s natural response to injury and disease.
While inflammation helps the body heal, long-term inflammation can contribute to tissue damage and worsen many chronic conditions.
Scientists have increasingly suspected that inflammation plays a larger role in osteoarthritis than previously believed. Although osteoarthritis has traditionally been viewed as a disease caused mainly by wear and tear, growing evidence suggests that chronic inflammation may also contribute to joint damage and disease progression.
To investigate whether reducing inflammation could help protect joints, researchers in the Netherlands conducted a large clinical trial involving more than 5,500 participants between the ages of 35 and 82. The study was carried out across 43 medical centers in Australia and the Netherlands.
Participants were randomly assigned to one of two groups. One group received a low daily dose of colchicine, just 0.5 milligrams per day. The other group received a placebo, a pill that looked identical but contained no active medication.
Neither the participants nor the researchers knew who was receiving the real medication during the study. This type of study design helps ensure the results are as reliable as possible.
The study lasted approximately 29 months, giving researchers enough time to observe whether the medication influenced long-term joint outcomes.
The results were encouraging. Among people taking colchicine, only 2.5% eventually required knee or hip replacement surgery. In comparison, 3.5% of participants taking the placebo underwent joint replacement surgery. Although the difference may seem modest, it represents a meaningful reduction in the number of surgeries needed.
For people living with osteoarthritis, avoiding or delaying joint replacement surgery can have a major impact on quality of life. Joint replacement procedures are generally successful, but they involve significant recovery time, rehabilitation, and potential complications.
Finding a medication that can slow disease progression could help many patients maintain mobility and independence for longer.
The researchers also found evidence suggesting that the benefits were more apparent in men. However, there were not enough female participants who underwent surgery during the study to determine with confidence whether women would experience the same level of benefit. Additional studies will be needed to answer this important question.
One reason the findings have generated excitement is that colchicine is already a well-known medication with an established safety record when used at appropriate doses. Developing entirely new drugs can take many years and cost enormous amounts of money. In contrast, colchicine is already widely available and relatively inexpensive.
If future studies confirm the results, doctors may be able to use colchicine as a practical and affordable way to slow joint damage and reduce the need for surgery in some patients with osteoarthritis.
The study also strengthens the growing theory that inflammation is a key driver of osteoarthritis progression. If inflammation contributes directly to cartilage breakdown and joint damage, targeting inflammatory processes could become an important strategy for treating the disease.
Despite the promising findings, experts caution that more research is necessary before colchicine becomes a standard treatment for osteoarthritis. Scientists still need to understand exactly how the medication protects joints, which patients are most likely to benefit, and whether long-term use is equally effective and safe for both men and women.
For now, people with osteoarthritis should continue following their healthcare provider’s advice. Lifestyle measures remain important for managing symptoms and protecting joint health.
Regular physical activity, maintaining a healthy body weight, strengthening muscles around the joints, and avoiding unnecessary joint strain can all help reduce pain and improve mobility.
The findings offer new hope for the millions of people living with osteoarthritis. A simple, affordable pill that has been available for decades may one day help people delay or even avoid major joint replacement surgery.
The study was published in the Annals of Internal Medicine.
Copyright © 2026 Knowridge Science Report. All rights reserved.
